 |
|
|
インターネットで調べることができるトリロスタンに関する情報（英語版のみ） Other references that may be of interest: Neiger R, Ramsey I, O'Connor J, Hurley KJ, Mooney CT (2002). Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticism. Veterinary Record 150, 799-804. Ruckstuhl NS, Nett CS, Reusch CE (2002). Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. Am J Vet Res 63, 506-512. Braddock JA, Church DB, Watson ADJ (2002). Trilostane and Selegiline evaluated for management of pituitary-dependent hyperadrenocorticism in dogs. BSAVA Congress, Birmingham, UK. Neiger R, Ramsey IK (2002). Trilostane therapy of canine hyperadrenocorticism. ACVIM Congress, Dallas, Texas. Neiger R and Hurley KJ (2001). 24 hour cortisol values in dogs with hyperadrenocorticism on trilostane. BSAVA Congress, Birmingham, UK. Eastwood JM, Elwood CM, Hurley KJ (2001). Trilostane treatment of four dogs with functional adrenocortical neoplasia. ESVIM congress, Dublin, Ireland. Ramsey I, McGrotty Y (2001). The effect of trilostane on ACTH stimulation tests performed at 2 different times post treatment. ESVIM congress, Dublin, Ireland. Neiger R and Campbell E (2000). 24 hour cortisol values after trilostane therapy in dogs with hyperadrenocorticism. ESVIM Congress, Switzerland. Neiger R and Hurley KJ (2000). Long term efficacy and safety of trilostane for the treatment of canine hyperadrenocorticism. JVIM 14, 376. Hurley KJ (1998). Trilostane in the treatment of canine hyperadrenocorticism. ESVIM congress, Vienna. Published in ESVIM Newsletter, Vol 9, #2, 1999. |
